HOW TO ENROLL YOUR PATIENT IN




Page 1: ENROLLMENT FORM

Select a service, complete the form, and have prescriber sign and date.

If no service option is selected, the patient will be enrolled in Full Access Services. SERVICE REQUESTED Full Access Services Patient Assistance Program (PAP) Additional instructions: **Full Access Services** Patient Assistance Program (PAP) **VELTASSA Starter Supply Only** One 20-day free trial of VELTASSA® • PAP eligibility review • One 20-day free trial of (patiromer) **VELTASSA** • Free VELTASSA to program-• Insurance benefit investigation eligible uninsured and • Full Access Services • Prior authorization and appeals underinsured patients available upon request assistance • One 20-day free trial • Only sections 1, 3, and 4 on of VELTASSA • Specialty pharmacy triage and page 1 of Enrollment Form coordination are required Co-pay and affordability assistance PAP eligibility review

Page 2: PRIVACY NOTICE & PATIENT AUTHORIZATION

Please have patient sign and date to enroll in requested Veltassa Konnect programs. Patient or patient's legal representative may also visit <u>www.VELTASSAeconsent.com</u> to provide authorization electronically. If patient signature is not available at the time of submission, Veltassa Konnect will follow up directly with the patient to try to obtain consent.



Page 3 (optional): PATIENT MARKETING CONSENT

Please have patient fill out, sign, and date page 3 to enroll in optional patient marketing programs.

V _K VeltassaKonnect* PATIENT MARKETING CONSENT I agree to receive additional disease and product information and to be contacted for mry opinions as part of Rehysta,		You may contact me by (Please mark $$ and fill in all of the methods by which you would like to be contacted):	
tic, I with "Phase Group Campan, and comparises and parties until must the highest collectables", Weighter or "Wile Phases" from which explores on the wholest a record per the related parties assistance program effectings; the contraction or contracting communications or marketing must include an explore and information or marketing must include about of the production or movine flower programs or related production. The production of the production or movine flower production of the production or movine flower production. The production of the p		✓ US Mail (✓ Use address from page 1)	
		☑ Email _janedoe@_ email.com	
Londonium die Boloweg		✓ Phone (_555_) _5555555	
		☑ Text messaging mobile phone number (<u>555</u>) <u>555</u> - <u>5555</u>	
		By providing your mobile phone number for texts or calls, you agree to marketing and nonmarketing messages from and on behalf of Relypsa using an automated telephone dialing system. This consent is not required to enroll in Relypsa services or purchase any products. Standard text messaging rates may apply.	
		3 3 7 11 7	
		Jave Doe Patient or Patient's Legal Representative Name (Print) Patient or Patient's Legal Representative (Signature) Date	



ENROLLMENT FORM

1. Complete each section and sign all pages.

2. Fax all pages to 1-888-623-7092.

QUESTIONS? 1-844-870-7597, Mon-Fri, 9 AM to 8 PM ET

SERVICE REQUESTED Full Access Services Pat (Select one)	rient Assistance Program (PAP) VELTASSA Starter Supply Only
Additional instructions:	_
1. Patient Information (Please provide physical address; no Polysical Address) Physical Address City State Zip Date of Birth / Male Female Primary Phone () Best Time to Call	Preferred Language Patient's Legal Representative Name(If applicable) Patient's Legal Representative Phone () Relationship to Patient
	y [both sides] of medical and/or prescription drug insurance cards.
3. Prescriber Information Prescriber Name	Treating Facility Name (e.g., name of practice, dialysis center, etc.)
Prescriber NPI	Treating Facility Address
Prescriber Tax ID	City State Zip
State License #	Treating Facility Contact Name Fax ()
4. VELTASSA® (patiromer) for oral suspension prescription Diagnosis ICD-10 Code(s) Hyperkalemia E87.5 Other VELTASSA Starter Supply*: Upon prescriber's medical assessment of pa a free trial offer of up to 20 days of VELTASSA. Yes, provide patient with a free supply of VELTASSA 8.4 g. Dissolv amount once daily. Dispense 20-day supply. 0 refills. Ship to patient's address Ship to treating facility address	atient need, Veltassa Konnect will provide eligible new patients with
	one (1) packet into 1/3 cup of water and drink full amount. Take as directed. sy supply Other times sy supply
Prescriber Declaration I certify that the patient and physician information contained in this enrollment form VELTASSA based on my judgment of medical necessity, and I will be supervising the transmittal of health information to Relypsa, Inc. (a Vifor Pharma Group Company), ar Pharma"), to perform a preliminary assessment of insurance verification and determ of this prescription to a dispensing specialty pharmacy on behalf of myself and the for any free product received through the program.	he patient's treatment. I have received the necessary authorization prior to the nd companies and parties working with Relypsa (collectively "Relypsa" or "Vifor nine patient eligibility for the Relypsa product program. I authorize the forwarding
	Prescriber Signature Date (No stamps; substitution permitted)

Patient Assistance Program (PAP) for uninsured applicants only

Annual pretax household income _____ Number of family members living in household

Uninsured PAP applicants are required to submit verification for all sources of household income at time of application, including a copy of one (1) of the following: most recent federal tax return, pay stub, W-2 statement, bank statement, or another source of income verification. This information will be used only to determine eligibility for the PAP. If you do not have one of the above-mentioned sources or if you have any change in your insurance or financial information, please call Veltassa Konnect at 1-844-870-7597.



PRIVACY NOTICE & PATIENT AUTHORIZATION

PATIENT SIGNATURE REQUIRED TO ENROLL IN VELTASSA KONNECT

By signing this Authorization, I authorize Relypsa, Inc. (a Vifor Pharma Group Company), and companies and parties working with Relypsa (collectively "Relypsa" or "Vifor Pharma"), to use and/or disclose my health information about my medical condition, records, treatment, and health plan for the purposes stated below. I also authorize my healthcare providers, my health plans, and my pharmacies to disclose my health information to Relypsa for the purposes stated below. I understand this Authorization is voluntary, but Relypsa cannot provide me services and information without it.

Veltassa Konnect is a program sponsored by Relypsa that provides patient support and helps eligible patients access, afford, be informed about, and comply with their treatment as prescribed. Any free product provided through the program cannot be submitted for reimbursement and shall be used as prescribed. Once my health information has been disclosed, I understand that privacy laws may no longer protect the information. However, Relypsa agrees to protect my health information by using and disclosing it only for purposes authorized in this Authorization or as required by law. I understand that certain parties, such as my pharmacy provider, may receive remuneration from Relypsa in connection with the activities described in this Authorization.

I authorize the use and/or disclosure of my health information for the following intended purposes only: (1) for my enrollment, determination of my eligibility, and my participation in Veltassa Konnect (and other related patient-assistance program offerings), and for the administration of the program; (2) to help communicate with me, my health plan, my provider, or my pharmacy about my medical care and insurance status; (3) to verify my insurance information; (4) to coordinate my prescription or medication through my healthcare provider and provide ongoing support for my treatment as prescribed; (5) to refer me to alternative third-party patient programs; and (6) to comply with law. I understand and agree that Relypsa may contact me by mail, email, phone, and/or text. Relypsa will generally leave voice messages with basic information. I authorize Relypsa to leave me voice messages with more detailed information about the reason for the call, which may contain more health information.

I understand that I may refuse to sign this Authorization and choose not to receive information or services from Relypsa. I understand that my treatment (including with a Relypsa product), payment for treatment, insurance enrollment, or eligibility for insurance benefits are not conditioned upon my agreement to sign this Authorization. I may cancel or modify this Authorization at any time by writing to Relypsa at Relypsa, Inc., PO Box 43848, Louisville, KY 40253. Canceling this Authorization will end my consent after the date Relypsa receives my letter but will not affect information previously disclosed pursuant to this Authorization.

This Authorization shall be in effect for five (5) years from the date of my signature, unless a shorter period is required by law or it is canceled in writing. This Authorization may be extended upon written notification by either Relypsa or myself. Upon expiration of this Authorization, all information will be destroyed. I may receive a copy of this Authorization upon request. I certify that all the information I provide to Relypsa is complete and accurate to the best of my knowledge.





PATIENT MARKETING CONSENT

I agree to receive additional disease and product information and to be contacted for my opinions as part of Relypsa, Inc., (a Vifor Pharma Group Company), and companies and parties working with Relypsa (collectively "Relypsa" or "Vifor Pharma") for marketing communications, which are separate from Veltassa Konnect (and other related patient-assistance program offerings).

These programs may include providing me with information or marketing materials about other products or services available from Relypsa and its affiliates, treatment reminders or education, or opportunities to participate in surveys or provide feedback. I understand my personally identifiable information (PII), including information about my use of Relypsa products, may be needed for me to be a part of these programs. I may choose to be contacted by mail, email, phone and/ or text. I understand the use and disclosure of my PII will be limited to Relypsa, its successors, and its agents, except as required by law. I agree to let Relypsa, its successors, or its agents contact me in the future about these programs.

You may contact me by (Please mark $\sqrt{\ }$ and fill in all of the methods by which you would like to be contacted):

I understand the following:

- I can receive my medicine even if I do not sign this consent
- I can receive assistance from Veltassa Konnect even if I do not sign this consent
- This consent to enroll in these programs or receive marketing information is voluntary
- · I may cancel my enrollment or consent to marketing at any time

IIS Mail (Ilse address from nage 1)

os man (osc adaress nom p	uge 1/	
Email		
Phone ()		
■ Text messaging mobile phone n	number ()	
, , , , ,	or calls, you agree to marketing and nonmarketing message tem. This consent is not required to enroll in Relypsa servi	,
,	Authorization at any time by writing to Relypsa, Inc 870-7597. For more information, you may view the privacy@relypsa.com.	
what personal information is collected about is collected about me, and to opt-out of the	ubject to certain restrictions, I may have the right at me, and the right to request that Relypsa delete sale of personal information about me. Relypsa w r Privacy Act (CCPA) rights. Any requests for disclos the Relypsa Privacy Policy.	personal information that ill not discriminate against
Patient or Patient's Legal Representative Name (Pri	nt) Patient or Patient's Legal Representative (Signature)	Date



